{"product_id":"cleveland-clinic-the-new-age-of-alzheimer-s-disease-therapeutics-2025","title":"Cleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: neurologists, primary care physicians, internists, geriatricians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe goal of this program is to provide healthcare professionals with the necessary tools, knowledge, and resources to confidently navigate these challenges. The conference will address critical aspects of anti-amyloid therapies in clinical practice, including cognitive assessment, patient selection, the pre-authorization process, infusion logistics, and the management of side effects like ARIA.\u003c\/p\u003e\n\u003cp\u003eTARGET AUDIENCE\u003c\/p\u003e\n\u003cp\u003eThis activity is designed for neurologists, primary care physicians (PCPs), internists, geriatricians, nurse practitioners, nurses, and other healthcare providers involved in the diagnosis, management, and treatment of patients with Alzheimer’s Disease or MCI.\u003c\/p\u003e\n\u003cp\u003eLEARNING OBJECTIVES\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this program, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eDescribe the clinical effects of anti-amyloid therapies and be able to convey to patients.\u003c\/p\u003e\n\u003cp\u003eIdentify patients that are candidates for anti-amyloid therapies.\u003c\/p\u003e\n\u003cp\u003eRecognize and monitor the potential complications of anti-amyloid therapies.\u003c\/p\u003e\n\u003cp\u003eList the administrative steps necessary to prescribe anti-amyloid therapies.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e01 Background on antiamyloid therapies Charles Bernick, MD, MPH\u003c\/p\u003e\n\u003cp\u003e02 Translating clinical trial results to the clinic Babak Tousi, MD\u003c\/p\u003e\n\u003cp\u003e03 Who is the right patient for anti-amyloid therapies Lakeshia Gibson, MD\u003c\/p\u003e\n\u003cp\u003e04 Surveillance for amyloid-related imaging abnormalities (ARIA) Dylan Wint, MD\u003c\/p\u003e\n\u003cp\u003e05 Logistics of starting anti-amyloid therapy Maileen Ulep, PhD, MSN, APRN, FNP-BC\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405803835588,"sku":null,"price":13.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Cleveland-Clinic-The-New-Age-of-Alzheimers-Disease-Therapeutics-2025.jpg?v=1784216423","url":"https:\/\/medicalcoursespro.com\/products\/cleveland-clinic-the-new-age-of-alzheimer-s-disease-therapeutics-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}